TECHNOLOGY TRANSFER AND SUPPLY AGREEMENTTechnology Transfer and Supply Agreement • May 7th, 2014 • Theravance Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT (this “Agreement”) is made as of this 22nd day of May, 2012 (the “Effective Date”) by and between Theravance, Inc., a Delaware Corporation having its principal place of business at 901 Gateway Blvd., South San Francisco, California, 94080 (“Theravance”) and Hospira Worldwide, Inc., a Delaware Corporation having its principal place of business at 275 North Field Drive, Lake Forest, Illinois, 60045 (“Hospira”).
EX-10.23 15 filename15.htmTechnology Transfer and Supply Agreement • May 5th, 2020 • New York
Confidential ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.
TECHNOLOGY TRANSFER AND SUPPLY AGREEMENTTechnology Transfer and Supply Agreement • May 14th, 2021 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances)
This TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT (this “AGREEMENT”) is made as of _________ __, 2013 by and between PROTALIX LTD. , a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B 455, Carmiel 20100, Israel (“PROTALIX”), and FUNDAÇÃO OSWALDO CRUZ , an agency of the Brazilian Ministry of Health organized under the laws of Brazil, including its manufacturing unit “BIO-MANGUINHOS”, with registered offices at Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, Cep 21045-900, Brazil, CGC NI 33.781.055/0001-35, represented by its President, Dr. PAULO ERNANI GADELHA VIEIRA, hereinafter collectively referred to as "FIOCRUZ". For the purposes of this AGREEMENT, PROTALIX and FIOCRUZ each are referred to as a “PARTY” and collectively as the “PARTIES”.
TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT BETWEEN: Sophiris Bio Corp. (Formerly Protox Therapeutics Corp.) California USA (hereinafter referred to as “Sophiris”) and Boehringer Ingelheim RCV GmbH & Co KG Dr. Boehringer Gasse 5-11 (hereinafter referred...Technology Transfer and Supply Agreement • February 15th, 2013 • Sophiris Bio Inc. • Pharmaceutical preparations • New York
WHEREAS, BI RCV and its Affiliate BIP (as defined below) own facilities specialised for GMP manufacture of biopharmaceuticals and employ personnel who have experience in process development, the production, quality control as well as in the registration of biopharmaceuticals for clinical trials and commercial sale in the United States, Europe and elsewhere; and
SECOND AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA ANTIBIOTICS, INC.Technology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Second Amendment to the Technology Transfer and Supply Agreement (“2nd Amendment”) is made and effective as of 17th day of October, 2014 (“ Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theravance Biopharma Antibiotics, Inc. (“Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this 2nd Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
FIRST AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE, INC.Technology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This First Amendment to the Technology Transfer and Supply Agreement (“Amendment”) is made and effective as of May 16, 2013 (“Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theravance, Inc. (“Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
TECHNOLOGY TRANSFER AND SUPPLY AGREEMENTTechnology Transfer and Supply Agreement • March 1st, 2010 • Genzyme Corp • Biological products, (no disgnostic substances) • Delaware
THIS TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT (hereinafter referred to as the “Agreement”) with an effective date of this 31st day of December 2009 (the “Effective Date”) is made by and between Genzyme Corporation, a Massachusetts corporation and Genzyme Therapeutics Products Limited Partnership, a Massachusetts Limited Partnership, each having its headquarters at 500 Kendall Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “GENZYME”), and Hospira Worldwide, Inc., a Delaware corporation having its headquarters at 275 North Field Drive, Lake Forest, Illinois, 60045, U.S.A. (hereinafter referred to as “HOSPIRA”).
THIRD AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA IRELAND LIMITEDTechnology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Third Amendment to the Technology Transfer and Supply Agreement (“3rd Amendment”) is made and effective as of April 14, 2016 (“Amendment Effective Date”), by and between Hospira Worldwide, Inc., (“Hospira”), and Theravance Biopharma Ireland Limited, the successor in interest to Theravance Biopharma Antibiotics, Inc. (“Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this 3rd Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein).
FOURTH AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between PFIZER, INC. and THERAVANCE BIOPHARMA IRELAND LIMITEDTechnology Transfer and Supply Agreement • November 9th, 2016 • Theravance Biopharma, Inc. • Pharmaceutical preparations
This Fourth Amendment to the Technology Transfer and Supply Agreement (“4th Amendment”) is made and effective as of September 29, 2016 (“Amendment Effective Date”), by and between the Pfizer CentreOne group of Pfizer, Inc., (as successor in interest to the One 2 One group of Hospira Worldwide, Inc., hereafter “Pfizer”), and Theravance Biopharma Ireland Limited (as successor in interest to Theravance Biopharma Antibiotics, Inc., hereafter, “Theravance”) each herein referred to individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this 4th Amendment that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined herein). References to numbered articles and sections cited herein refer to specific articles or sections of the Agreement.
